Best mRNA / LNP CDMOs in Europe

← All mRNA/LNP CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

125

EMA/MHRA GMP certs

Warning letters

For European-manufactured mrna / lnp programs, ReciBioPharm, BioNTech (Mfg Services), and FUJIFILM Diosynth Biotechnologies lead CDMO Signal's ranking of mrna / lnp CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 36 scored mrna / lnp CDMOs to 17 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.

Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 4 NAI (no action), 21 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Germany (34), United States (24), Italy (21), UNITED KINGDOM (20), Denmark (17).

Last updated 2026-07-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
2	BNT BioNTech (Mfg Services) Mainz, DE · Marburg, DE	84.8	100.0	0 insp · 8 GMP	—	27 programs
3	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK	83.5	100.0	0 insp · 23 GMP	Expanding	0 programs
4	CD Corden Pharma Plankstadt, DE · Caponago, IT · Boulder, CO	82.5	99.7	3 insp · 10 GMP	—	0 programs
5	MK Merck KGaA / MilliporeSigma (CDMO) Darmstadt, DE · St. Louis, MO	81.8	98.6	2 insp · 2 GMP	—	22 programs
6	WK Wacker Biotech Jena, DE · Amsterdam, NL · San Diego, CA	81.6	100.0	0 insp · 13 GMP	—	0 programs
7	KE Kaneka Eurogentec Seraing, BE	80.3	100.0	0 insp · 4 GMP	—	0 programs
8	Lonza Basel, Switzerland	78.2	95.1	2 insp · 8 GMP	—	1 programs
9	Catalent Bagsværd, Denmark (operating under Novo Holdings)	76.5	79.3	11 insp · 35 GMP	—	0 programs
10	CVC CureVac (CDMO Services) Tubingen, DE	75.3	100.0	0 insp · 7 GMP	—	4 programs
11	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	75.1	79.3	1 insp · 0 GMP	Available	0 programs
12	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
13	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	72.8	95.1	1 insp · 0 GMP	Limited	0 programs
14	BP BSP Pharmaceuticals Latina, Italy	67.6	77.4	7 insp · 12 GMP	—	0 programs
15	HP HIPRA Biotech Services Amer, ES	63.0	—	—	—	0 programs
16	QB Quantoom Biosciences Gosselies, BE	56.5	—	—	—	0 programs
17	EH Ethris Planegg, DE	56.5	—	—	—	0 programs
—	Roche / Genentech (Internal Manufacturing & CustomBiotech) Basel, Switzerland	Profiled	—	—	—	0 programs
—	53Biologics Boecillo (Valladolid), Spain	Profiled	—	—	—	0 programs
—	Centillion Technology Limited Newcastle upon Tyne, United Kingdom	Profiled	—	—	—	0 programs
—	Ardena Ghent, Belgium	Profiled	—	—	—	0 programs
—	Touchlight Hampton, United Kingdom	Profiled	—	—	—	0 programs
—	Eppendorf BioBLU Hamburg, Germany	Profiled	—	—	—	0 programs
—	Curapath Spain (exact city not disclosed publicly)	Profiled	—	—	—	0 programs
—	Croda Pharma (formerly Avanti Polar Lipids) Snaith, United Kingdom	Profiled	—	—	—	0 programs
—	BioSpring GmbH Frankfurt, Germany	Profiled	—	—	—	0 programs
—	Thermo Fisher Scientific / Patheon – Monza, Italy Monza, Italy	Profiled	—	—	—	0 programs
—	Fresenius Kabi Bad Homburg, Germany	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a mRNA / LNP CDMO

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

mRNA / LNP CDMOs — Frequently Asked Questions

Who are the top mRNA / LNP CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include ReciBioPharm, BioNTech (Mfg Services), FUJIFILM Diosynth Biotechnologies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many mRNA / LNP CDMOs have FDA inspection records?

CDMO Signal tracks 7 mRNA / LNP CDMOs with FDA inspection records and 125 EMA/MHRA GMP certificates across the group.

What should I look for in an mRNA / LNP CDMO?

Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.

Do mRNA CDMOs also make the LNP and plasmid?

Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.

Related modalities

Plasmid DNA CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC